Abstract
It is important to calculate the proper sample size for a thorough QTc study to ensure adequate study power without enrolling unnecessary subjects. In current practice, at least two tasks need to be performed to rule out clinically relevant QT liability of the study drug: (a) demonstrate that the largest 90% two-sided upper confidence bound for the baseline-adjusted mean differences between the study drug and the placebo is less than 10 ms; and (b) establish assay sensitivity of the study. Traditionally, the sample size is determined by the primary task (a), and then subjects are equally assigned into each treatment arm. This practice might not be the most appropriate method. In this article, an optimal sample size allocation scheme is introduced and discussed.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
International Conference on Harmonisation. ICH E14 Guidance. The clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs. Geneva, Switzerland: International Conference on Harmonisation; May 2005.
Zhang J, Machado SG. Statistical issues including design and sample size calculation. J Biopharm Stat. 2008;18:451–467.
Zhang J. Testing for positive control activity in a thorough QTc study. J Biopharm Stat. 2008;18: 517–528.
Zhang L, Dmitrienko A, Luta G. Sample size calculations in thorough QT studies. J Biopharm Stat. 2008;18:468–482.
Chow SC, Cheng B, Cosmatos D. On power and sample size calculation for QT studies with recording replicates at given time point. J Biopharm Stat. 2008;18:483–493.
Julious SA. Sample sizes for clinical trials with normal data. Stat Med. 2004;23:1921–1986.
Anand SP, Murray SC, Koch GG. Sample size calculations for crossover thorough QT studies: satisfaction of regulatory threshold and assay sensitivity. J Biopharm Stat. 2010;20:563–579.
Meng Z, Kringle R, Chen X, Zhao PL. Sample size calculation for thorough QT/QTc study considering various factors related to multiple time points. J Biopharm Stat. 2010;20:580–594.
Hosmane B, Locke C, Chiu YL. Sample size and power estimation in thorough QT/QTc studies. J Biopharm Stat. 2010;20:595–603.
Tsong Y, Yan LK, Zhong J, Nie L, Zhang J. Multiple comparisons of repeatedly measured response: issues of validation testing in thorough QT/QTc clinical trials. J Biopharm Stat. 2010;20:654–664.
Zhang J. Thorough QT study design and baseline issues. Paper presented at DIA Cardiovascular Safety in Drug Development: QT, Arrhythmias, Thrombosis, and Bleeding. 2009.
Yan L, Zhang J, Ng MJ, Dang Q. Statistical characteristics of moxifloxacin-induced QTc effect. J Biopharm Stat. 2010;20:497–507.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Zhang, J. Optimal Sample Size Allocation in a Thorough QTc Study. Ther Innov Regul Sci 45, 455–468 (2011). https://doi.org/10.1177/009286151104500407
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1177/009286151104500407